- HDSA Research
- Grant Applications
- Research News & Reports
- Research Webinar Series
- Kids-HD: Brain Imaging Research Study
- Omeros PDE10 inhibitor (OMS-643762) trial
- Presymtomatic Testing for HD
- Survey: The role of genetic counselors
- A Brief Guide to the Clinical Trial Process
- Find the Clinical Trials In Your Area
- International Enroll-HD Sites
- Clinical Trials Diplomats
- HDBuzz Research News
- HD Gene Symposium: 20 Years
- Therapies in Pipeline
- Research Conferences
- Scientific Advisory Board
- Research Pipeline
- Stem Cells
- HD Insights
- HD Glossary
- Links to Other Research
- Reports Library
- Research Investors Reports
- Video Postcard from 2014 HD Therapeutics Conference
Pride-HD is a Phase II clinical research study of an investigational drug called pridopidine in people who have a diagnosis of Huntington disease (HD). The purpose of this study to see what effect pridopidine has on movement, thinking, and behavior, compared to placebo (a capsule that looks like pridopidine but has no active ingredient), in people with Huntington’s Disease.
Pridopidine, the investigational drug being studied may have an effect on some of the symptoms of Huntington’s Disease that depend on dopamine. Dopamine is a substance that is naturally made by the human body. It is made in many areas of the brain, and affects how people behave, think and move. It has been suggested that changes in the way dopamine works in Huntington’s Disease creates signs and symptoms of the condition. This study is being conducted to determine if pridopidine helps with the signs and symptoms of Huntington’s Disease.
Pride-HD is a joint collaboration between the Huntington Study Group (HSG) and the European Huntington’s Disease Network (EHDN). 400 participants will be enrolled globally at approximately 51 study sites. Participants will receive either pridopidine or placebo for 26 weeks.
Click here for more detailed eligibility information and exclusion criteria.